Efficacy and safety of folfiri plus aflibercept in second-line treatment of metastatic colorectal cancer
Makaleler > Tam Makale · 2022
Yazarlar: Cihan Erol, Mehmet Ali Nahit Sendur, Irem Bilgetekin, Duygu Bayir Garbioglu, Jamshid Hamdard, Sinem Akbas, Mutlu Hizal, Cagatay Arslan, Alper Sevinc, Ahmet Kucukarda, Dilek Erdem, Seda Kahraman, Emre Cakir, Aykut Demirkiran, Sercan On, Izzet Dogan, Atike Pinar Erdogan, Sinan Koca, Pinar Kubilay, Orhan Onder Eren, Ebru Cilbir, Emir Celik, Murat Araz, Deniz Tataroglu Ozyukseler, Mahmut Emre Yildirim, Aykut Bahceci, Halil Taskaynatan, Abdilkerim Oyman, Gulhan Ipek Deniz, Serkan Menekse, Engin Kut, Ahmet Gulmez, Abdullah Sakin, Erdinc Nayir, Ramazan Acar, Erdem Sen, Ali Inal, Serdar Turhal, Ali Osman Kaya, Semra Paydas, Didem Tastekin, Ilhan Hacibekiroglu, Irfan Cincin, Ahmet Bilici, Nil Molinas Mandel, Didem Sener Dede, Muhammed Bulent Akinci, Berna Oksuzoglu, Dogan Uncu, Bulent Yalcin, Mehmet Artac
Journal of Cancer Research and Therapeutics, Uluslararası, Wos, 2022, cilt 18, ss S347-S353
DOI: 10.4103/jcrt.jcrt_1104_21
Özet
Aims: The addition of aflibercept to the fluorouracil and irinotecan (FOLFIRI) regimen significantly improved clinical outcomes in patients with metastatic colorectal cancer (CRC) previously treated with oxaliplatin. We aimed to investigate the efficacy and safety of second-line FOLFIRI and aflibercept combination in patients with metastatic CRC in real-life experience. Materials and Methods: Four hundred and thirty-three patients who treated with FOLFIRI and aflibercept in the second-line were included in the study. The clinical and pathological features of the patients were recorded retrospectively. Survival (overall and progression-free survival [PFS]), response rates, and safety data were analyzed. Results: The median age was 61. Majority of patients (87.5%) received first-line bevacizumab and 10.1% of patients received anti-epidermal growth factor receptor agents. About 80% of patients had KRAS, 18.6% of patients had NRAS, and 6.4% of patients had BRAF mutations. The median OS was 11.6 months (95% confidence interval [CI], 10.6-12.6) and the median PFS was 6 months (95% CI, 5.5-6.5). About 4.6% of patients had complete response and 30.6% of patients had partial response as best tumor response. Grade 1-2 toxicities were seen in 33.4% of patients, while grade 3-4 toxicities were recorded in 27% of patients. Eight patients (2%) died due to treatment toxicity. Conclusions: Overall and PFS were similar in routine clinical practice compared to phase III pivotal VELOUR trial. However, response rates were found to be higher. It was observed that there were fewer adverse events compared to the VELOUR trial.